|
1
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jo VY and Fletcher CD: WHO classification
of soft tissue tumours: An update based on the 2013 (4th) edition.
Pathology. 46:95–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gorlick R, Janeway K, Lessnick S, Randall
RL, Marina N and Committee COGBT: COG Bone Tumor Committee:
Children's oncology group's 2013 blueprint for research: Bone
tumors. Pediatr Blood Cancer. 60:1009–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
8
|
Krichevsky AM and Gabriely G: miR-21: A
small multi-faceted RNA. J Cell Mol Med. 13:39–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH,
Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, et al: MicroRNA-26a
suppresses epithelial-mesenchymal transition in human
hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
J Hematol Oncol. 9:12016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyamoto K, Seki N, Matsushita R, Yonemori
M, Yoshino H, Nakagawa M and Enokida H: Tumour-suppressive
miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by
regulating PLOD2 in bladder cancer. Br J Cancer. 115:354–363. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson KR, Lehn DA and Reeves R:
Alternative processing of mRNAs encoding mammalian chromosomal
high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol.
9:2114–2123. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grosschedl R, Giese K and Pagel J: HMG
domain proteins: Architectural elements in the assembly of
nucleoprotein structures. Trends Genet. 10:94–100. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thanos D and Maniatis T: The high mobility
group protein HMG I (Y) is required for NF-kappa B-dependent virus
induction of the human IFN-beta gene. Cell. 71:777–789. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah SN and Resar LM: High mobility group
A1 and cancer: Potential biomarker and therapeutic target. Histol
Histopathol. 27:567–579. 2012.PubMed/NCBI
|
|
17
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
18
|
Pierantoni GM, Agosti V, Fedele M, Bond H,
Caliendo I, Chiappetta G, Lo Coco F, Pane F, Turco MC, Morrone G,
et al: High-mobility group A1 proteins are overexpressed in human
leukaemias. Biochem J. 372:145–150. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Puca F, Colamaio M, Federico A, Gemei M,
Tosti N, Bastos AU, Del Vecchio L, Pece S, Battista S and Fusco A:
HMGA1 silencing restores normal stem cell characteristics in colon
cancer stem cells by increasing p53 levels. Oncotarget.
5:3234–3245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW,
Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, et al: Crucial role
of HMGA1 in the self-renewal and drug resistance of ovarian cancer
stem cells. Exp Mol Med. 48:e2552016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu G, Wang J, Jia Y, Shen F, Han W and
Kang Y: MiR-142-3p functions as a potential tumor suppressor in
human osteosarcoma by targeting HMGA1. Cell Physiol Biochem.
33:1329–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wan J and Zhang X, Liu T and Zhang X:
Strategies and developments of immunotherapies in osteosarcoma.
Oncol Lett. 11:511–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Velletri T, Xie N, Wang Y, Huang Y, Yang
Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, et al: P53 functional
abnormality in mesenchymal stem cells promotes osteosarcoma
development. Cell Death Dis. 7:e20152016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ji J, Shi J, Budhu A, Yu Z, Forgues M,
Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kota J, Chivukula RR, O'Donnell KA,
Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P,
Torbenson M, Clark KR, et al: Therapeutic microRNA delivery
suppresses tumorigenesis in a murine liver cancer model. Cell.
137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu J, Song G, Tang Q, Yin J, Zou C, Zhao
Z, Xie X, Xu H, Huang G, Wang J, et al: MiR-26a inhibits stem
cell-like phenotype and tumor growth of osteosarcoma by targeting
Jagged1. Oncogene. 36:231–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D,
Wang L, Wang YJ, Zong Y, Wu YD, et al: MiR-26a and miR-144 inhibit
proliferation and metastasis of esophageal squamous cell cancer by
inhibiting cyclooxygenase-2. Oncotarget. 7:15173–15186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu X, Dong B, Tian Y, Lefebvre P, Meng Z,
Wang X, Pattou F, Han W, Wang X, Lou F, et al: MicroRNA-26a
regulates insulin sensitivity and metabolism of glucose and lipids.
J Clin Invest. 125:2497–2509. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fu X, Jin L, Wang X, Luo A, Hu J, Zheng X,
Tsark WM, Riggs AD, Ku HT and Huang W: MicroRNA-26a targets ten
eleven translocation enzymes and is regulated during pancreatic
cell differentiation. Proc Natl Acad Sci USA. 110:17892–17897.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang P and Lv L: miR-26a induced the
suppression of tumor growth of cholangiocarcinoma via KRT19
approach. Oncotarget. 7:81367–81376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma X, Dong W, Su Z, Zhao L, Miao Y, Li N,
Zhou H and Jia L: Functional roles of sialylation in breast cancer
progression through miR-26a/26b targeting ST8SIA4. Cell Death Dis.
7:e25612016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu S, Wang T, Yang Z, Li Y, Li W, Wang T,
Wang S, Jia L, Zhang S and Li S: miR-26a desensitizes non-small
cell lung cancer cells to tyrosine kinase inhibitors by targeting
PTPN13. Oncotarget. 7:45687–45701. 2016.PubMed/NCBI
|
|
33
|
Yu C, Li J, Sun F, Cui J, Fang H and Sui
G: Expression and clinical significance of miR-26a and pleomorphic
adenoma gene 1 (PLAG1) in invasive pituitary adenoma. Med Sci
Monit. 22:5101–5108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pegoraro S, Ros G, Ciani Y, Sgarra R,
Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates
breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pegoraro S, Ros G, Piazza S, Sommaggio R,
Ciani Y, Rosato A, Sgarra R, Del Sal G and Manfioletti G: HMGA1
promotes metastatic processes in basal-like breast cancer
regulating EMT and stemness. Oncotarget. 4:1293–1308. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Esposito F, De Martino M, Petti MG,
Forzati F, Tornincasa M, Federico A, Arra C, Pierantoni GM and
Fusco A: HMGA1 pseudogenes as candidate proto-oncogenic competitive
endogenous RNAs. Oncotarget. 5:8341–8354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lau KM, Chan QK, Pang JC, Ma FM, Li KK,
Yeung WW, Cheng AS, Feng H, Chung NY, Li HM, et al: Overexpression
of HMGA1 deregulates tumor growth via cdc25A and alters
migration/invasion through a cdc25A-independent pathway in
medulloblastoma. Acta Neuropathol. 123:553–571. 2012. View Article : Google Scholar : PubMed/NCBI
|
